Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ceftriaxone
Drug ID BADD_D00405
Description Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic.[A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627]. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.[A215582]
Indications and Usage For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
Marketing Status Prescription; Discontinued
ATC Code J01DD04
DrugBank ID DB01212
KEGG ID D07659
MeSH ID D002443
PubChem ID 5479530
TTD Drug ID D07ACT
NDC Product Code 66794-214; 71205-593; 68071-4713; 44567-702; 66794-215; 70518-3355; 68180-633; 0143-9859; 50090-0945; 63187-435; 66794-213; 64679-702; 64679-701; 25021-106; 0143-9678; 68180-622; 25021-105; 66794-212; 25021-107; 0264-3155; 44567-700; 64679-703; 66794-211; 44567-703; 0143-9856; 71205-117; 0143-9858; 68071-4715; 72572-061; 68180-611; 68071-4304; 64679-983; 68071-4303; 44567-701; 0264-3153; 0143-9857; 63323-346; 68180-644; 72572-062; 50090-2628
Synonyms Ceftriaxone | Ceftriaxon | Cefatriaxone | Ceftriaxone, Disodium Salt, Hemiheptahydrate | Ceftrex | Ceftriaxon Curamed | Ceftriaxon Hexal | Ceftriaxona Andreu | Ceftriaxona LDP Torlan | Ceftriaxone Irex | Ceftriaxone Sodium | Ceftriaxone Sodium, Anhydrous | Anhydrous Ceftriaxone Sodium | Lendacin | Longacef | Longaceph | Ro13-9904 | Ro13 9904 | Ro139904 | Ro-13-9904 | Ro 13-9904 | Ro 13 9904 | Ro 139904 | Rocephin | Rocefalin | Rocephine | Rocefin | Tacex | Terbac | Ceftriaxone, Disodium Salt | Benaxona | Cefaxona
Chemical Information
Molecular Formula C18H18N8O7S3
CAS Registry Number 73384-59-5
SMILES CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphocyte morphology abnormal13.01.06.0150.020426%Not Available
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.061278%Not Available
Ureteral disorder20.06.01.0040.030639%Not Available
Renal impairment20.01.03.010--Not Available
Unevaluable event08.01.03.051--Not Available
Hepatic enzyme abnormal13.03.01.0200.030639%Not Available
Chronic kidney disease20.01.03.017--
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.061278%Not Available
Bone marrow failure01.03.03.0050.071490%
Localised intraabdominal fluid collection07.07.01.0070.030639%Not Available
Treatment failure08.06.01.0170.037299%Not Available
Liver injury12.01.02.003; 09.01.07.0220.040852%Not Available
Low birth weight baby18.04.02.0030.030639%Not Available
Urinary casts present13.13.02.009--Not Available
Cholestatic liver injury09.01.07.0160.020426%Not Available
Hypertransaminasaemia09.01.02.0050.030639%Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.0080.020426%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Kounis syndrome24.04.04.020; 10.01.03.037; 02.02.02.0200.122555%Not Available
Acute kidney injury20.01.03.0161.409383%
Use of accessory respiratory muscles22.02.08.0170.020426%Not Available
Langerhans' cell histiocytosis22.01.01.016; 16.21.04.003; 15.09.03.008; 01.13.04.0030.020426%Not Available
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.005328%Not Available
Craniocerebral injury17.11.01.007; 12.01.10.0120.020426%Not Available
Drug-induced liver injury09.01.07.023; 12.03.01.0440.459581%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.0210.428943%Not Available
Autoimmune haemolytic anaemia10.04.01.005; 01.06.01.0040.047956%Not Available
Candida infection11.03.03.0210.051065%
Immune thrombocytopenic purpura10.04.01.008; 01.08.01.0070.030639%Not Available
Mouth swelling10.01.05.020; 23.04.01.020; 07.05.04.0070.020426%Not Available
The 17th Page    First    Pre   17 18    Next   Last    Total 18 Pages